Global Exosomes Pipeline Insight Report 2021: Insights on Approx 50+ Companies and 70+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Exosomes – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Exosomes – Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 70+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Exosomes: Overview

Exosomes have therapeutic potential to control many diseases, along with aid in disease diagnosis. The intrinsic properties of exosomes in regulating complex intracellular pathways have advanced their potential utility in controlling many diseases, including neurodegenerative conditions and cancer.

Exosomes can be engineered to deliver diverse therapeutic payloads, including short interfering RNAs, antisense oligonucleotides, chemotherapeutic agents, and immune modulators, with the ability to direct their delivery to the desired target.

The lipid and protein composition of exosomes can affect their pharmacokinetic properties, and their natural constituents may play a role in minimizing adverse reactions and enhancing bioavailability. The efficient exchange of cellular components through exosomes inform their applied use in designing exosome-based therapeutics.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Exosomes R&D. The therapies under development are focused on novel approaches for Exosomes.

Exosomes Emerging Drugs Chapters

This segment of the Exosomes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Exosomes Emerging Drugs

CAP-1002: Capricor

Capricor’s core therapeutic technology (CAP-1002) is based on cardiosphere-derived cells, or CDCs – a cardiac-derived cell therapy, first identified in the academic laboratory of Capricor’s scientific founder, Dr. Eduardo Marban. Since the initial publication in 2007, CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 200 human subjects across several clinical trials. CAP-1002 consists of allogeneic “off-the-shelf” cardiosphere-derived cells, or CDCs, a type of cardiac cell therapy that has been shown in preclinical and clinical studies to exert potent Immunomodulatory activity.

It is being investigated for its potential to modify the immune system’s activity to encourage cellular regeneration. The cells function by releasing exosomes that are taken up largely by macrophages and T-cells and begin a cycle of repair.

It is currently in Phase II for Covid-19, Duchenne Muscular Dystrophy and Phase I for Dilated Cardiomyopathy (DCM), Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, and Heart Failure.

ExoFlo: Direct Biologics

ExoFlo is an investigational new drug that has not been approved or licensed by the FDA. It is an extracellular vesicle product isolated from human bone marrow mesenchymal stem or stromal cells (MSCs). ExoFlo provides natural bioactive signals that have shown to modulate inflammation and direct cellular communication. Preclinical studies of these extracellular vesicles secreted by bone marrow-derived mesenchymal stem cells (bmMSCs) suggest that they may have the ability to downregulate inflammation and upregulate tissue repair in humans.

In October 2020, The US Food and Drug Administration (FDA) granted expanded access for Direct Biologics’ ExoFlo, allowing it to be used to treat patients with COVID-19-associated acute respiratory distress syndrome. It is currently in phase II stage of development and is being developed by Direct Biologics.

Exosomes: Therapeutic Assessment

This segment of the report provides insights about the different Exosomes drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Exosomes

There are approx. 50+ key companies which are developing the Exosomes. The companies which have their Exosomes drug candidates in the most advanced stage, i.e. Phase II include, Capricor.

Current Scenario and Emerging Therapies:

• How many companies are developing Exosomes drugs?
• How many Exosomes drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Exosomes?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Exosomes therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Exosomes and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Capricor Therapeutics
• Direct Biologics
• Progenza
• AVEM HealthCare
• Aegle Therapeutics
• Cellular Biomedicine Group
• Organicell Regenerative Medicine
• Codiak BioSciences
• United Therapeutics
• ArunA Biomedical
• Evox Therapeutics
• MolecuVax
• Versatope Therapeutics
• Lamellar Biomedical
• Azymus Therapeutics
• Ciloa
• Alxerion Biotech
• Exovita Biosciences
• Avalon GloboCare
• NeurExo Sciences
• Celltex Therapeutics
• Stem Cell Medicine
• Regenasome
• Exerkine
• Cells for Cells
• ReNeuron
• Tavec Pharmaceuticals
• Therapeutic Solutions International
• Exogenus Therapeutics
• Ilias
• XoStem
• Aluda Pharma
• Coya Therapeutics
• Vivazome

Key Products

• CAP-1002
• ExoFlo
• Progenza
• Mesenchymal stem cells (MSCs) – exosomes
• Mesenchymal progenitor cells (MPCs) derived exosomes
• AGLE 102
• Zofin
• exoIL 12
• exoSTING
• UNEX 42
• AB 126
• EVX-102
• AB 127
• EVX-101
• AB 128
• exoASO-STAT6
• MVAX 001
• VT 105
• IPF Lamellasome
• Muco-ease
• ALX-029
• ALX-102
• AVA 201
• AVA 203
• CAP 2003
• Exosome mRNA Vaccine
• Exosome VLP Display Vaccine
• Mesenchymal stem cell derived vesicles
• Human placental amniotic epithelial stem cells (hAECs)
• Biologic for Genetic diseases
• Exosomes OA
• ExoPr0
• TVC 201
• StemVacs derived exosomes
• Exo-101
• Exo-Target
• XO VENT
• XO NEUR
• XO HAIR
• XO SKIN
• Exosome Release Inhibitors (ExoRIs)
• EAITM- Exosome Against Inflammation platform

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/o2nwil

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900